Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Cut by Analyst

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Zacks Research cut their Q1 2025 earnings estimates for shares of Esperion Therapeutics in a note issued to investors on Tuesday, October 1st. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of ($0.15) per share for the quarter, down from their previous estimate of ($0.13). The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.04) per share. Zacks Research also issued estimates for Esperion Therapeutics' Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at $0.16 EPS, Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.14 EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at $0.15 EPS and FY2026 earnings at $0.07 EPS.

Several other brokerages also recently weighed in on ESPR. Needham & Company LLC reduced their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating for the company in a research report on Tuesday, August 13th. StockNews.com cut shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, September 27th. Bank of America downgraded shares of Esperion Therapeutics from a "neutral" rating to an "underperform" rating and decreased their price objective for the company from $2.90 to $2.50 in a research note on Thursday, June 20th. Finally, HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Wednesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, Esperion Therapeutics presently has an average rating of "Hold" and an average price target of $8.17.

Esperion Therapeutics Trading Up 10.2 %

ESPR stock traded up $0.20 during trading on Friday, hitting $2.16. 4,491,174 shares of the company's stock were exchanged, compared to its average volume of 6,492,427. The business has a 50-day moving average price of $1.85 and a two-hundred day moving average price of $2.19. The stock has a market capitalization of $409.23 million, a price-to-earnings ratio of -2.11 and a beta of 1.00. Esperion Therapeutics has a 52-week low of $0.70 and a 52-week high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to analysts' expectations of $51.90 million.

Institutional Investors Weigh In On Esperion Therapeutics

Several hedge funds have recently made changes to their positions in the business. Bellevue Group AG increased its position in Esperion Therapeutics by 136.5% in the 1st quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company's stock valued at $26,650,000 after acquiring an additional 5,739,800 shares during the period. Wasatch Advisors LP increased its holdings in shares of Esperion Therapeutics by 2.7% in the first quarter. Wasatch Advisors LP now owns 9,129,647 shares of the biopharmaceutical company's stock valued at $24,467,000 after purchasing an additional 238,544 shares during the period. Vanguard Group Inc. raised its stake in shares of Esperion Therapeutics by 71.8% during the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company's stock worth $23,655,000 after purchasing an additional 3,688,796 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Esperion Therapeutics by 94.2% during the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company's stock worth $9,554,000 after purchasing an additional 2,087,635 shares during the period. Finally, GSA Capital Partners LLP grew its position in Esperion Therapeutics by 1.0% in the 4th quarter. GSA Capital Partners LLP now owns 1,128,149 shares of the biopharmaceutical company's stock valued at $3,373,000 after buying an additional 11,494 shares during the last quarter. Institutional investors and hedge funds own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.